Open access
Open access
Powered by Google Translator Translator

Covid-19

Perspective | Don’t Be Surprised When Vaccinated People Get Infected

24 Mar, 2021 | 08:28h | UTC

Don’t Be Surprised When Vaccinated People Get Infected – The Atlantic

 


Opinion | Perfect as the enemy of good: tracing transmissions with low-sensitivity tests to mitigate SARS-CoV-2 outbreaks

24 Mar, 2021 | 08:22h | UTC

Perfect as the enemy of good: tracing transmissions with low-sensitivity tests to mitigate SARS-CoV-2 outbreaks – The Lancet Microbe

 

Commentary on Twitter

 


[Press release – not published yet] AstraZeneca vaccine 79% effective for preventing symptomatic COVID-19

23 Mar, 2021 | 02:36h | UTC

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis – AstraZeneca

Commentaries: AstraZeneca vaccine is 79% effective against symptomatic Covid-19, company says – CNN AND AstraZeneca’s Covid-19 vaccine shows better-than-expected efficacy in U.S. trial – STAT AND Expert reaction to press release from AstraZeneca announcing interim data on safety and efficacy from the US trial of the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca Publishes Reassuring Trial Data, But Vaccine Hesitancy Remains Widespread In European Union – Health Policy Watch

 


Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

23 Mar, 2021 | 02:33h | UTC

SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery – Anaesthesia

Related: Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk – Anaesthesia

 

Commentary on Twitter

 


EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials

23 Mar, 2021 | 02:30h | UTC

EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials – European Medicines Agency

Related: FDA: Why you should not use Ivermectin to treat or prevent COVID-19 (statement, commentary, and RCT)

 


Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

23 Mar, 2021 | 02:28h | UTC

We need to start thinking more critically — and speaking more cautiously — about long Covid – STAT

 


Review | Post-acute COVID-19 syndrome

23 Mar, 2021 | 02:26h | UTC

Post-acute COVID-19 syndrome – Nature Medicine

News Release: Study underscores need for multidisciplinary care for COVID-19 long-haulers – Dana-Farber Cancer Institute

 


Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study

23 Mar, 2021 | 02:20h | UTC

Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study – Intensive Care Medicine

 

Commentary on Twitter

 


Editorial | Scholarly communications harmed by covid-19

23 Mar, 2021 | 02:25h | UTC

Scholarly communications harmed by covid-19 – The BMJ

 

Commentaries on Twitter

 


Covid-19 disruptions killed 228,000 children in South Asia, says UN report

23 Mar, 2021 | 02:22h | UTC

Covid-19 disruptions killed 228,000 children in South Asia, says UN report – BBC

Report: Direct and indirect effects of the COVID-19 pandemic and response in South Asia – United Nations

 


Opinion | An open plea for dignity and respect in science

23 Mar, 2021 | 02:24h | UTC

An open plea for dignity and respect in science – The BMJ Opinion

Related: Scientists who express different views on Covid-19 should be heard, not demonized – STAT

 

Commentary on Twitter

 


Expert consensus statements for the management of COVID-19-related acute respiratory failure

21 Mar, 2021 | 22:05h | UTC

Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method – Critical Care

 

Commentary on Twitter

 


Infection and mRNA vaccine-induced immunity may be retained against SARS-CoV-2 variant B.1.1.7

21 Mar, 2021 | 22:04h | UTC

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination – JAMA

 


SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination

21 Mar, 2021 | 22:02h | UTC

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies – Cell

 


CDC Guidance for schools says students can now stay 3 feet apart, rather than 6

21 Mar, 2021 | 22:07h | UTC

CDC Guidance: CDC Updates Operational Strategy for K-12 Schools to Reflect New Evidence on Physical Distance in Classrooms – Centers for Disease Control and Prevention

See also: Operational Strategy for K-12 Schools through Phased Prevention – Centers for Disease Control and Prevention

Commentaries: CDC Says Schools Can Now Space Students 3 Feet Apart, Rather Than 6 – NPR AND CDC updates COVID school guidance, OKs 3-feet distancing – CIDRAP

Related: Cohort study: Effectiveness of three vs. six feet of physical distancing for controlling spread of COVID-19 among primary and secondary students and staff (study and commentary)

 

Commentaries on Twitter

 


[Preprint] Oxford/AstraZeneca and Pfizer/BioNTech vaccines probably can still neutralize P.1 strain of SARS-CoV-2, but at lower levels

21 Mar, 2021 | 21:55h | UTC

Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 – bioRxiv

Commentary: Existing COVID vaccines may protect against Brazilian variant – Oxford study – Reuters

 


B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.

21 Mar, 2021 | 21:52h | UTC

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera – Cell

 


Bioethics | “Europe’s Vaccine Ethics Call: Do No Harm and Let More Die?”

21 Mar, 2021 | 21:50h | UTC

Europe’s Vaccine Ethics Call: Do No Harm and Let More Die? – The New York Times (free registration may be required)

Related opinion: Covid-19 vaccine adverse events: balancing monitoring with confidence in vaccines – The BMJ Opinion

See also: European Medicines Agency finds AstraZeneca vaccine is safe and benefits outweigh the risks (Statement and commentaries) AND Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine – World Health Organization AND Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)

 

Commentary on Twitter

 


Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

21 Mar, 2021 | 21:49h | UTC

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review – Journal of the American College of Cardiologyv

 

Commentary on Twitter

 


Modeling Study: Vaccination alone is unlikely to contain COVID-19 infections in UK

21 Mar, 2021 | 21:46h | UTC

Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study – The Lancet Infectious Diseases

Commentaries: Risking further COVID-19 waves despite vaccination – The Lancet Infectious Diseases AND Vaccination alone is unlikely to contain COVID-19 infections in UK – The Lancet

 

Commentary on Twitter

 


Clinician Guide to COVID-19 diagnostics in children

21 Mar, 2021 | 21:48h | UTC

Clinician guide to COVID-19 diagnostics – ADC Education & Practice

 


RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

19 Mar, 2021 | 08:42h | UTC

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial – JAMA

Editorial: Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19 – JAMA

 

Commentary on Twitter

 


European Medicines Agency finds AstraZeneca vaccine is safe and benefits outweigh the risks

19 Mar, 2021 | 08:37h | UTC

COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets – European Medicines Agency

Commentaries: Restoring confidence after the covid-19 Oxford/AstraZeneca vaccine pause will be an uphill battle – The BMJ Opinion AND European Medicines Agency: AstraZeneca Vaccine Safe – Benefits Outweigh Risks – Despite Possible Rare Events – Health Policy Watch AND Expert reaction to announcement from EMA on Oxford-AstraZeneca vaccine and blood clots – Science Media Centre AND European regulators say AstraZeneca vaccine safe, but can’t rule out rare events – CIDRAP AND AstraZeneca vaccine safe, but rare risk of blood clots not ruled out, EU regulator says – LiveScience AND European Medicines Agency Finds AstraZeneca Vaccine Safe And Effective – NPR

 


Current evidence for COVID-19 therapies: a systematic literature review

19 Mar, 2021 | 08:36h | UTC

Current evidence for COVID-19 therapies: a systematic literature review – European Respiratory Review

 


SARS-CoV-2 transmission without symptoms

19 Mar, 2021 | 08:30h | UTC

SARS-CoV-2 transmission without symptoms – Science (a few articles per month are free)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.